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Summary  
Five years post-PCV13, pneumococcal carriage has decreased among PCV13 vaccinated infants and 
their mothers, however some vaccine serotypes such as serotypes 3, 7F and 19A have persisted and 
some non-vaccine serotypes such as serotype 21 and non-typeable strains have emerged.  
Abstract  
Background  
The widespread use of pneumococcal conjugate vaccine (PCV) has brought about a dramatic 
decrease in pneumococci of vaccine serotypes (VT) but non-vaccine serotypes (NVT) have emerged. 
Robust data on VT persistence and the extent of NVT replacement in developing countries are 
crucial to guide future vaccine policy.  
Methods  
We conducted a cross sectional survey (CSS) among infants who received three doses of PCV13 and 
their mothers five years (CSS3) after PCV13 introduction. Nasopharyngeal swabs were collected and 
cultured for isolation of Streptococcus pneumoniae. Whole genome sequencing of the non-typeable 
strains was performed. Data were compared to two previous surveys conducted before PCV13 
introduction (CSS1), and one year (CSS2) later.  
Results  
Among infants, VT carriage decreased from 33.3% (113/339) in CSS1 to 11.4% (40/351) in CSS3 
(p=0.001) while NVT increased from 53.1% (180/339) in CSS1 to 74.4% (261/351) in CSS3 (p <0.001). 
Among mothers, there was a significant decrease of VT between CSS2 8.4% (29/347) and CSS3 5.6% 
(19/342) (p=0.006). NVT increased from 16.6% (55/331) in CSS1 to 32.2% (110/342) in CSS3 
(p<0.001). In CSS3, the most prevalent VT were 7F (infants) and 3 (mothers), and NVT were 
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serogroup 16 and non-typeables respectively. Genomic analysis showed that VT were more likely 
than NVT to lose their ability to express the capsule.  
Conclusions  
Five years after PCV13, we show both direct (infants) and indirect effects (mothers) of the vaccine, 
while NVT replacement has occurred in both groups. Ongoing circulation of VT warrants further 
study of its relevance in any consideration of a reduced dose schedule. 
Keywords  
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Introduction  
Prevention of pneumococcal disease remains a major global health priority due to the high disease 
burden and associated mortality, especially among children in developing countries (1). A seven-
valent vaccine (PCV7) was licensed in 2009, but higher valency formulations (PCV10 and PCV13) have 
since been licenced (2). WHO recommends worldwide PCV introduction particularly in countries with 
under-5 mortality of >50/1000 live births (3). To date PCVs have been introduced in 59 low and 
middle income countries (4).   
The impact of PCVs on pneumococcal disease results from a combination of the direct and indirect 
effects of the vaccine (5-7). The latter is a consequence of decreased carriage prevalence among 
vaccinated individuals and the resulting decrease in pneumococcal transmission within communities 
(8, 9). The overall vaccine impact on both disease and carriage, however, has been dampened by an 
increase in serotypes not included in the vaccine formulations, i.e., non-vaccine serotypes (NVT). 
This phenomenon is known as serotype replacement (10, 11). Fortunately, the lower virulence of 
NVT means there is nonetheless a net reduction in pneumococcal disease after PCV introduction (12, 
13). In addition to serotype replacement, increased capsular switching (genetic recombination of the 
proteins on the bacterial capsule) in response to vaccine pressure has been reported (14).  
In The Gambia where PCV7 was introduced in 2009 and replaced by PCV13 in 2011, we reported an 
82% reduction in vaccine serotype (VT) invasive pneumococcal disease (IPD) and 47% increase in 
NVT IPD two years after PCV13 introduction (15). These data are consistent with data from two 
successive carriage surveys conducted before PCV13 introduction (two years after PCV7 and one 
year before PCV13) which showed a decrease in PCV13 VT carriage in infants but not their mothers 
(i.e. no herd effect). Despite the decrease in VT, a third of all pneumococcal isolates were of VT (16).  
Interestingly, an increase in the prevalence of carriage with non-typeable pneumococci, the majority 
of which had lost their capsule, was also observed (16).  
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The increase in NVT carriage and the continued presence of VT both in carriage and disease, post 
PCV are a cause for concern. To continue monitoring the direct and indirect effect of PCV13 among 
vaccinated infants and their unvaccinated mothers on overall, VT and NVT carriage, and to explore 
vaccine impact on non-typeable strains, we conducted a third pneumococcal carriage survey, five 
years after PCV13 introduction.  
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Methods  
Study setting 
The study was carried out at two government health facilities that offer maternal and child health 
services with regular Expanded Programme on Immunisation (EPI) clinics. PCV13 was introduced 
without a catch-up in a 3+0 schedule with doses given at 2, 3 and 4 months. The WHO/UNICEF 
immunisation data reported > 95% coverage of PCV13 dose 3 in 2016 (17).  
Study design 
We conducted a cross sectional survey (CSS3) five years after PCV13 in 2016. The results were 
compared with historical data from two earlier surveys conducted before PCV13 in 2011 (CSS1) and 
one year after PCV13 in 2012 (CSS2) (16). The study design, recruitment sites, entry criteria, sample 
collection and laboratory methods were similar and all three surveys were conducted between 
March and June. In all three surveys, we recruited healthy infants 6-12 months of age and their 
mothers at the EPI clinics. Infants were recruited only if they had received three doses of PCV13, at 
least 1 month before recruitment and were accompanied by their biological mother. We collected 
information on demographics and risk factors for carriage by interviewing the mothers. 
Nasopharyngeal swabs (NPS) were collected from the mothers and their infants. Written informed 
consent was obtained from the mothers. The study was approved by the joint Medical Research 
Council (MRCG)-Gambia Government Ethics Committee.  
NPS sample collection  
A calcium alginate swab was passed gently down the posterior wall of the nasopharynx. The swab 
was remove and placed in skim milk–tryptone–glucose–glycerol (STGG) transport medium. The STGG 
vials were taken to MRCG laboratories as recommended (18, 19).  
Laboratory processing 
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The samples were stored at – 70°C and processed as previously described for CSS1 and CSS2 (16). In 
brief, 200µl of thawed, vortexed STGG was placed into 5ml of Todd Hewitt broth containing 5% yeast 
extract, and 1ml of rabbit serum. This mixture was vortexed and then incubated at 37°C for 4-6 
hours. Subsequently, 50µl aliquot was inoculated onto gentamycin blood agar and incubated 
overnight in 5% CO2 at 37°C for the selective isolation of S. pneumoniae. The morphologically distinct 
alpha haemolytic colonies were screened for optochin susceptibility. Serotyping was done using 
latex agglutination technique (20). As in CSS1 and CSS2, serotyping was repeated for all non-typeable 
isolates.  
Whole genome sequencing for non-typeable pneumococcal serotypes 
Twenty nine non-typeable isolates from CSS1 and CSS2 were previously analysed using whole 
genome sequencing at the Wellcome Sanger Institute (Cambridge, UK). In this study, we analysed a 
further 23 non-typeables obtained from CSS3.  
The sequencing, identification of contaminants, and MLST were done as detailed previously (16). The 
phylogenetic tree was  reconstructed from SNP-sites (21) using RAxML (22). In-silico serotype was 
determined using the k-mer based serotyping method, SeroBA (23). This identified serotypes and 
generated capsule loci gene assemblies. No assemblies were generated for classical non-typeable 
pneumococci or isolates that have lost their capsule synthesis genes. Assemblies were annotated 
using Prokka (24). To investigate potential reasons for the non-capsule  expression, all capsule loci 
were compared to reference capsule loci derived from Bentley et al (25) using Artemis Comparison 
Tool [ACT] (26). Genes showing significant difference to the reference genes were aligned and 
visualised in SeaView to investigate for truncations and mutations that may cause loss of function. 
Sample size calculation  
We targeted 350 infants similar to the sample size in CSS1 and CSS2. This provided 90% power to 
detect a 50% reduction in the prevalence of PCV13 VT and a 25% increase in NVT compared to CSS2, 
i.e., a decrease of PCV13 VT prevalence from 18% to 9% among infants and 8.1% to 4.1% among 
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mothers, and an increase of PCV13 NVT prevalence from 66.3% to 82.9% among infants and 16.1% 
to 20.1% among mothers (16).  
Data management and analysis  
We calculated PCV7 carriage prevalence (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F), PCV13 carriage 
prevalence (PCV7 serotypes +1, 3, 5, 6A, 7F, 19A) and PCV13 NVT carriage prevalence (all other 
serotypes including non-typeables). Additionally we calculated the prevalence of the six serotypes 
contained in PCV13 but not in PCV7. We used Poisson regression with robust standard errors to 
estimate prevalence ratios comparing CSS1 & CSS3, and CSS2 & CSS3 and to adjust for potential 
confounders. We tested the hypothesis that the proportion of PCV13 VT was the same among 
‘typeables’ (i.e., isolates of known serotypes) and non-typeables (16) using Fisher’s exact test. All 
analyses were done using STATA 14 (Statacorp LP, USA). 
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Results  
Characteristics of the study participants  
We recruited 351 infants and 347 mothers in CSS3. A total of 1020 mothers and 1040 infants were 
swabbed over the three surveys (20 infants were twins). Across the surveys, the median (IQR) age 
was 25 years (21.0-29.3) for mothers and 7.9 months (6.8-9.4) for infants and 51.8% of the infants 
were males.  The demographical and epidemiological characteristics of the women and infants were 
similar across the surveys except that in CSS1 mothers were less educated and infant antibiotic use 
was more common (Table 1).  
Prevalence of pneumococcal carriage pre and five years post-PCV13  
Vaccinated Infants  
Overall carriage was approximately 85% over the three surveys (Table 2). VT pneumococcal carriage 
decreased from 33.3% (113/339) in CSS1 to 11.4% (40/351) in CSS3 (p<0.001) while NVT carriage 
increased from 53.1% (180/339) in CSS1 to 74.4% (261/351) in CSS3 (p<0.001).  VT decreased further 
between CSS2 and CSS3 (18.3% to 11.4%, p=0.021) while NVT increased (66.9% to 74.4%, p=0.025) 
(Table 2). For the six serotypes included in PCV13 but not in PCV7, there was a significant decrease in 
prevalence between CSS1 and CSS2 (23.9% versus 13.7%), with an additional drop to 5.4% in CSS3 
(p<0.001).     
Among vaccine-type serotypes, 19A decreased from 8.3% in CSS1 to 0.9% in CSS3 (p< 0.001) and 19F 
decreased slightly from 5.6% to 2.8% (p=0.078). Serotype 6A decreased from 15.3% in CSS1 to 5.7% 
in CSS2 (p<0.001). The most prevalent VT in CSS3 was serotype 7F (3.4%) which had not been seen in 
the previous surveys (p<0.001). Serotype 21 was the second most prevalent NVT (7.1%) having 
increased significantly from CSS1 (3.2%, p=0.026) and there was a significant increase in the non-
typeables from 0.3% in CCS1 to 3.4% in CSS3 (p=0.018).  
Mothers of vaccinated infants 
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Overall pneumococcal carriage increased from 23.0% (76/331) in CSS1 to 37.7% (129/342) in CSS3 
(p<0.001) (Table 3). Although prevalence of VT carriage was similar in all three surveys (6%), NVT 
carriage increased from 16.6% (55/331) in CSS1 to 32.2% (110/342) in CSS3 (Table 3).  
Serotype 3 was the most prevalent VT in CSS3 (1.8%) followed by 19F (1.2%). Other VT serotypes 
that were prevalent in CSS1 and CSS2, decreased considerably [19A decreased from 1.8% in CSS1 to 
0.3% in CSS3, and 6A from 1.8% in CSS1 to 0% in CSS3 (p=0.014)]. Several NVT increased between 
CSS1 and CSS3. Notably serotype 21 increased from 0.9% in CSS1 to 2.9% in CSS3 (p=0.073) and non-
typeables increased from 0.3% in CSS1 to 3.2% in CSS3 (p=0.023) (Table 3).  
Genotypic analysis of the non-typeable serotypes 
A total of 52 phenotypically non-typeable isolates were analysed; three from CSS1 (two from 
mothers and one from an infant), 26 from CSS2 (five from mothers and 21 from infants) and 23 from 
CSS3 (11 from mothers and 12 from infants). Three isolates were S. pseudopneumoniae - one from a 
mother in CSS1 and two isolates from infants in CSS2 (16), and one was a non-pneumococcal 
streptococcus from a mother in CSS3. Fifteen isolates (28.8%) were of the classical non-typeable 
lineage. The others (33; 63.5%) were of an encapsulated pneumococcal lineage and had lost their 
ability to express a capsule through three different mechanisms (Figure 1 and Table 4).  Eight had a 
standard capsular polysaccharide synthesis (cps) locus but a capsule was not phenotypically 
detected, 15 had indels in capsule synthesis genes or complete loss of capsule loci and 10 had 
acquired a locus typically found in classically non-typeable isolates.  
Based on combined data from CSS2 and CSS3, eight mothers and 19 infants carried non-typeables 
that were non classical [seven (87.5%) and eight (42.1%) were of the VT lineage respectively]. 
Compared to VT carriage prevalence of 22.6% (49/217) in mothers and 17.5% (104/595) in infants, 
this corresponds to 3.9 fold increase (95% CI 2.7, 5.6; p<0.001) in mothers and 2.4 fold increase (95% 
CI 1.4-4.2, p=0.012) in infants.  
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Discussion  
Despite the observed decline in VT pneumococcal prevalence in mothers and infants since the 
introduction of PCV13 in The Gambia, VT pneumococci continue to circulate in both groups. Among 
infants, the decrease in PCV13 VT carriage and associated increase in NVT resulted in no change in 
overall pneumococcal carriage. In contrast, the decrease in VT in mothers was less pronounced than 
the increase in NVT resulting in a net increase in overall pneumococcal carriage. Our previous 
observation that the increase in non-typeable pneumococcus post PCV is mainly due to serotypes 
that have lost their capsule was confirmed by data from CSS3 (16). 
Although the direct effect of PCV13 on circulating PCV13 VT among vaccinated infants was observed 
one year after its introduction (CSS2) (16), five years later (CSS3) VT were  still circulating in infants 
who had received three  doses of the vaccine. The PCV13 VT prevalence in this study (11.4%) is 
similar to VT carriage among Gambian new-borns two years after routine PCV13 (27), but two fold 
higher than PCV13 VT prevalence in Greenlandic under-fives  (5%) three years after PCV13 (28), 
Belgian children  (5.4%) five years after PCV13 and nine years after PCV7 (29), and Australian 
Aboriginal under-fives (5.8%) three years after PCV13 and ten years after PCV7 (30).  We saw a 
significant increase in serotype 19F after PCV13 introduction which was also among the most 
common VT after PCV13 in the Belgian study (29).  We also observed an increase in serotype 7F 
prevalence in CSS3.  The increase is surprising since a mathematical model of pneumococcal 
transmission in The Gambia predicted that PCV13 would eliminate low transmission VT including 7F 
(31). A similar increase in 7F was observed in IPD surveillance data after introduction of PCV13 in 
Australia. However, elsewhere there has been a decline in 7F post-PCV13 (32).  
Our results suggest a PCV13 herd effect among Gambian mothers of vaccinated infants, particularly 
for serotypes 6A and 19A; such an effect was not yet apparent one year after the introduction of 
PCV13 (CSS2). However, we have to interpret this decrease in VT with caution as the decrease 
between CSS1 and CSS3 was not significant, and there was an increase between CSS1 and CSS2 
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driven by the large increase in serotype 19A in CSS2. A cluster randomised trial that was conducted 
in rural Gambia demonstrated a herd effect of PCV (33), as have countries that have introduced 
PCV7 (34) and  countries that have introduced PCV13 with a booster dose (6).   
We found that the prevalence of serotype 19A decreased after PCV13 introduction and was low in 
CSS3 in both mothers and infants. This is in contrast to data from the UK and Alaska. In the UK, one 
of the first countries to switch from PCV7 to PCV13, IPD associated with 19A has begun to increase in 
recent years (35) and in Alaska, PCV13 protection against 19A is waning in older vaccinated children 
possibly due to the emergence of a new genotype. Longer surveillance in our setting is needed to 
better understand the trend of this serotype in carriage and disease 
In mothers, serotype 3 was the most prevalent serotype in CSS3, and cases of IPD caused by this 
serotype are still seen in The Gambia (15). This serotype, which had already decreased before PCV13 
introduction, shows secular trends in The Gambia (36). Several carriage and IPD studies have shown 
that PCV13 has no direct or indirect effect on serotype 3 (37, 38). 
Five years post-PCV13, we have observed an increase of NVT both for vaccinated infants and their 
mothers. For infants, we had already observed an increase between CSS1 and CSS2. In CSS3, we 
detected a significant increase in serotypes 21 and 23B. These were also the most prevalent 
serotypes in the post-PCV13 era in studies conducted in The Gambia (27), Italy and Norway (39, 40). 
Unexpectedly, among mothers the increase in NVT exceeded the decrease in VT, resulting in an 
overall increase in carriage. Although this large increase is difficult to explain, it probably reflects an 
upsurge in pneumococcal transmission, rather than biased sampling since similar field and 
laboratory methods were used in all three surveys and recruitment took place during the same time 
of the year to minimise any effect of season (41).  
Non-typeable strains increased in prevalence over the three surveys in both vaccinated infants and 
mothers which is consistent with the rise in non-typeable strains causing non-invasive and invasive 
disease after PCV13 introduction in Taiwan (42). Further WGS analysis of all the non-typeables 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy726/5079135
by London School of Hygiene & Tropical Medicine user
on 03 September 2018
  
confirmed our previous hypothesis that VT are more likely than NVT to lose their ability to express 
the capsule after introduction of PCV. These ‘capsular switches’ may be due to the selection of 
variants that existed in the pre-PCV era. Capsular loss is relatively common for S. pneumoniae, and 
increased loss due to vaccine pressure has also been reported in other studies (14).  
Non-typeable pneumococci are  likely to be under-reported (43) as they are generally excluded from 
the analyses in epidemiological studies and  vaccine trials, including the ongoing surveillance of the 
IPD in The Gambia (15). This maybe because their role in disease has been limited. For example, in 
South Africa over a 10 year period spanning from before to post PCV, and in the US over a three year 
period in the post-PCV era, non-typeables rarely caused disease (44, 45). We nonetheless advocate 
for the inclusion of non-typeable strains in epidemiological surveillance studies due to their 
increasing importance and potential for maintaining transmission.  
The three surveys provide valuable data on the timeliness of vaccination. It is often assumed that 
vaccination in Africa is substantially delayed and more in line with a 2+1 schedule (i.e., two doses 
before 6 months and one “booster dose” after 9 months). However, our data suggest that in The 
Gambia the schedule used is close to 3+0 (the median age of PCV dose 3 vaccination was 5 months). 
Our study therefore represents a genuine evaluation of the 3+0 schedule and, as such, contributes 
to the current debate over the relative merits of the 3+0 versus the 2+1 PCV schedule (46). 
The main limitations of our study were intrinsic to the study design in that we cannot exclude secular 
trends in individual serotypes since variability in the prevalence of serotypes were already described 
before vaccine introduction (47). In addition our surveys only started after PCV7 was introduced into 
routine immunisation and therefore our comparisons were between children vaccinated with PCV7 
(CSS1) and children vaccinated with PCV13 (CSS2 and CSS3), capturing only the additional effect of 
PCV13 over PCV7. There may have been residual confounding since we did not adjust for number of 
siblings, and other studies have shown increased risk of carriage when living with other children (27, 
47). However, there was no difference in maternal age between surveys, a potential proxy for 
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number of siblings. And though we did not collect information on household size in CSS3, there was 
no association between carriage and household size in CSS1 and CSS2. 
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Conclusions 
We have shown important effects of the introduction of PCV13 into routine immunization in The 
Gambia, including direct and indirect effect, and serotype replacement. Continued disease 
surveillance and additional carriage surveys are necessary to monitor persistence of VT, the 
emergence of NVT, and the role of non-typeables in transmission and disease. An alternative 
vaccination schedule (not necessarily reducing the number of doses) needs to be considered to halt 
ongoing VT transmission.  
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Tables  
Table 1 Characteristics of the study participants  
 CSS1*^ N=339 CSS2*^ N=350 CSS3^ N=351 P-value¬ 
Variable  n(%) n(%) n(%)  
Era** Before PCV13  1 year after 5 years after  
Health centre      
        Jammeh Foundation 229(67.6)  251(71.7) 250(71.2) 0.428 
        Sukuta  110(32.4) 99(28.3) 101(28.8)  
     
Gender a     
        Male 180(53.1) 165(47.3) 195(55.6) 0.069 
        Female  159(46.9) 184(52.7) 156(44.4)  
Infant’s age  (months)                
         Median (IQR) 8.2 (7.0,9.6) 7.6 (6.7,9.2) 8.0 (6.9,9.3)  
Infant PCV age (weeks)     
         Median (IQR)     
         Dose 1 10.3 (9.3,11.9) 10.6 (9.3, 12.3) 10.0 (9.0, 11.6)  
         Dose 2 15.9 (14.1, 18.3) 16.6 (14.6, 18.7) 15.4 (14.0-17.7)  
         Dose 3b 21.9 (19.4, 24.9) 22.4 (20.1, 25.6) 20.7 (18.9, 23.4)  
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Infant antibiotic use c      
         No 295(88.6) 319(92.2) 333(94.9) 0.010 
         Yes  38(11.4) 27(7.8) 18(5.1)  
     
Mother’s schooling d     
         None or < 1 year  134(41.7) 108(31.3) 135(39.5) <0.001 
         1-3 years  44(13.7) 35(10.1) 8(2.3)  
         4-6 years  78(24.3) 44(12.8) 26(7.6)  
         >6 years  65(20.3) 158(45.8) 173(50.6)  
Mother’s age (years)       
         Median(IQR) 24.5 (21.0,29.0) 25.0 (21.0,28.0) 25.0 (21.0, 30.0)  
Household size      
Median (IQR) 5.0 (4.0,7.0) 3.0 (3.0,5.0) Na  
*Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme 
of Immunization in The Gambia Roca et al, Vaccine 33 (2015) 7144–7151)  
^ There were 20 twins; CSS1 8, CSS2 3 & CSS3 9. The number of mothers was 331, 341 and 347 in CSS1, 2 and 3 
respectively.  
**PCV 7 intro in 2009, two years before the start of this study 
¬ p-value obtained from chi-square test. 
a
 one missing in CSS2  
b
 one missing in CSS3 
b six missing CSS1 and 2 missing CSS2  
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c
 antibiotic use within 4 months of survey  
d 
10 missing in CSS1 and 2 missing in CCS2 
Na   Not available as data were not collected 
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Table 2 
Prevalence of pneumococcal carriage in Infants before (CSS1) and one (CSS2) and five years (CSS3) after introduction of PCV13 into the Gambian EPI. 
 Prevalence of Carriage (%) CSS2 versus CSS3 CSS1 versus CSS3 
 
CSS1(N=339) CSS2(N=350) CSS3(N=351) RRadj p-value RRadj p-value 
Vaccine groups  
    
  
  PCV 13 VT 33.3 18.3 11.4 0.64(0.44,0.93) 0.021 0.60(0.50,0.71) <0.001 
PCV 13 NVT  53.1 66.9 74.4 1.12(1.01,1.23) 0.025 1.19(1.11,1.26) <0.001 
PCV13-7 VT 23.9 13.7 5.4 0.40(0.24,0.67) 0.001 0.23(0.14,0.37)  <0.001 
PCV 7 VT 9.4 4.9 6.0 1.30(0.67,2.53) 0.441 0.67(0.31,1.00) 0.051 
All serotypes 85.8 84.3 85.5 1.02(0.96,1.09) 0.459 1.00(0.97,1.04) 0.885 
     
  
  PCV 13 VT 
    
  
  1 0 0 0 NA  NA NA NA 
3 0 0.3 1.1 3.99(0.45,35.56) 0.215 NA NA 
4 0.6 0 0.9 NA  NA 1.20(0.49,2.94) 0.684 
5 0.3 1.4 0 NA  NA NA NA 
6A 15.3 5.7 0 NA  NA NA NA 
6B 0.9 0 0 NA  NA NA NA 
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7F 0 0 3.4 NA  NA NA NA 
9V 0 0 0.6 NA  NA NA NA 
14 0.6 0.9 0.6 0.66(0.11,3.96) 0.654 0.98(0.37,2.61) 0.972 
18C 0.6 0 0 NA  NA NA NA 
19A 8.3 6.3 0.9 0.14(0.04,0.45) 0.001 0.32(0.18,0.58) <0.001 
19F 5.6 1.7 2.8 1.66(0.61,4.53) 0.32 0.71(0.49,1.04) 0.078 
23F 1.5 2.3 1.1 0.50(0.15,1.64) 0.252 0.88(0.46,1.69) 0.699 
     
  
  PCV 13 NVT 
    
  
  10A 4.7 4 6 1.50(0.77,2.89) 0.232 1.13(0.82,1.55) 0.463 
13 3.5 3.4 3.4 1.00(0.45,2.19) 0.994 0.98(0.66,1.46) 0.931 
15B 8.3 9.1 6.8 0.75(0.45,1.24) 0.263 0.91(0.70,1.18) 0.48 
16 5.9 6.6 9.7 1.47(0.89,2.45) 0.135 1.28(0.98,1.67) 0.068 
19C 0.9 0.3 0 NA  NA NA NA 
21 3.2 4.9 7.1 1.47(0.81,2.67) 0.21 1.48(1.05,2.10) 0.026 
23B 1.5 3.1 4.6 1.45(0.68,3.08) 0.334 1.76(1.07,2.89) 0.026 
34 3.8 2.3 4.6 1.99(0.86,4.60) 0.106 1.09(0.76,1.56) 0.637 
35B 4.7 4.9 4.6 0.94(0.48,1.83) 0.852 0.98(0.70,1.38) 0.92 
NT 0.3 6.0 3.4 0.57(0.28,1.14) 0.112 3.40(1.23,9.42) 0.018 
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RR risk ratio, RRadj risk ratio adjusted for health centre, maternal age, and maternal education infant’s age, gender, and antibiotic intake within four weeks of the 
survey  
Table 3 
Prevalence of pneumococcal carriage in Mothers before (CSS1) and one (CSS2) and five years (CSS3) after introduction of PCV13 into the Gambian EPI.  
 Prevalence of Carriage (%) CSS2 versus CSS3 CSS1 versus CSS3 
 
CSS1(N=331) CSS2(N=347) CSS3(N=342) RRadj pvalue RRadj p-value 
Vaccine group 
    
  
  PCV 13 VT 6.6 8.4 5.6 0.58(0.33,1.02) 0.06 0.92(0.67,1.27) 0.627 
PCV 13 NVT 16.6 16.1 32.2 2.01(1.51,2.67) <0.001 1.40(1.20,1.63) <0.001 
PCV 13-7 VT 3.9 6.1 2.3 0.34(0.15,0.74) 0.007 0.65(0.28,,1.52) 0.319 
PCV 7 VT  2.7 2.6 3.2 1.14(0.46,2.79) 0.782 0.99(0.40-2.48) 0.989 
All serotypes 23.0 24.2 37.7 1.51(1.20,1.91) <0.001 1.29(1.14,1.47) <0.001 
     
  
  PCV13 VT 
    
  
  1 0.3 0 0 NA  NA NA NA 
3 0 0.3 1.8 6.09(0.74,50.38) 0.094 NA NA 
4 0.6 0.6 0.6 1.01(0.14,7.17) 0.988 0.98(0.37,2.62) 0.974 
5 0 0.9 0 NA  NA NA NA 
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6A 1.8 2 0 NA  NA NA NA 
6B 0 0 0 NA  NA NA NA 
7F 0 0 0.3 NA  NA NA NA 
9V 0 0 0.3 NA  NA NA Na 
14 0.6 0.3 0.6 2.03(0.18,22.31) 0.563 0.98(0.37,2.62) 0.974 
18C 0.3 0.6 0.3 0.51(0.05,5.58) 0.579 0.98(0.25,3.93) 0.982 
19A 1.8 3.2 0.3 0.09(0.01,0.71) 0.022 0.40(0.14,1.16) 0.091 
19F 0.6 0.3 1.2 4.06(0.46,36.19) 0.21 1.39(0.60,3.24) 0.444 
23F 0.6 0.9 0.3 0.34(0.04,3.24) 0.347 0.70(0.21,2.31) 0.553 
     
  
  PCV13 NVT 
    
  
  10A 0.6 0.3 2.3 8.12(1.02,64.65) 0.048 1.97(0.91,4.26) 0.086 
13 0.6 1.7 0.6 0.34(0.07,1.67) 0.183 0.98(0.37,2.62) 0.974 
15B 0.6 1.7 1.2 0.68(0.19,2.38) 0.542 1.39(0.60,3.24) 0.444 
16 2.4 0.6 2.3 4.06(0.87,19.00) 0.075 0.98(0.61,1.60) 0.947 
19C 1.2 0 0 NA   NA NA 
21 0.9 0.9 2.9 3.38(0.94,12.19) 0.063 1.80(0.95,3.41) 0.073 
23B 0 0.9 2.0 2.37(0.62,9.09) 0.209 NA NA 
34 1.2 1.2 1.8 1.52(0.43,5.35) 0.513 1.20(0.64,2.26) 0.561 
35B 1.8 0.6 1.8 3.04(0.62,14.99) 0.171 0.98(0.56,1.72) 0.954 
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NT 0.3 1.4 3.2 2.23(0.78,6.36) 0.133 3.26(1.17,9.06) 0.023 
RR risk ratio, RRadj risk ratio adjusted for health centre, maternal age, and maternal education 
Table 4 Results of whole genome sequencing of non-typeable isolatesa 
Isolate N Mother 
/Infant 
S.pn  % 
reads 
S.pseudopn % 
reads 
ST Nearest 
ST 
Capsular locus 
top hit 
Serotype 
specific 
sequence 
detected 
Ancestral 
capsular type 
from phylogeny 
Conclusion VT 
/NVT 
CSS1           
108887 Infant 78.08 0.71 3407  16F 16F 16F Wzd gene loss and 
truncated wzh 
NVT 
105098 Mother 80.51 0.14 1778  34 34 34 Intact capsule synthesis 
genes- No genetic 
explanation 
NVT 
104550 Mother 19.47 40.9 Unknown  -   S.pseudopneumoniae --- 
CSS2           
201376 Infant 80.46 0.25 5521  10A 10A 10A Intact capsule synthesis 
genes- No genetic 
NVT 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy726/5079135
by London School of Hygiene & Tropical Medicine user
on 03 September 2018
  
explanation 
207381 Infant 82.09 0.4 Novel ST D 2052 20 20 Long branch, 
inconclusive 
Truncated whaF and wzx 
genes 
NVT 
206628 Infant 81.38 0.08 989  12F 12F/A/46 12F/A/46 Intact capsule synthesis 
genes- No genetic 
explanation 
NVT 
210240 Infant 80.96 0.08 989  12F 12F/A/46 12F/A/46 Intact capsule synthesis 
genes- No genetic 
explanation 
NVT 
210201 Infant 83.51 0.08 2447  14 14 14 Truncated glycosyl 
transferase genes, wciY 
and lrp 
VT 
201867
b
 Infant 46.64 0.57 Novel ST B 4040 Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
200954 Mother 81.22 0.25 Novel ST G 975 15B/C 15B/C 15B/C 12 nucleotide insertion at 
the 5’ end of the initial 
transferase gene, wchA 
NVT 
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206379 Infant 81.51 0.16 4033  15B/C 15B/C 15B/C 12 nucleotide insertion at 
the 5’ end of the initial 
transferase gene, wchA 
NVT 
207139 Infant 76.55 0.57 3407  16F 16F 16F Wzd gene loss and 
truncated wzh 
NVT 
210300 Infant 78.96 0.62 Novel ST F 3407 16F 16F 16F Wzd gene loss and 
truncated wzh 
NVT 
210092 Infant 80.13 0.28 Novel ST E 847 19A 19A 19A 3 nucleotide deletion at the 
3” end of the rmlC gene 
VT 
210344 Infant 79.93 0.19 Unknown 7661 19B  19B Intact capsule synthesis 
genes- No genetic 
explanation 
NVT 
206438 Infant 81.8 0.1 202  19A 19A Long branch, 
inconclusive 
3 nucleotide deletion at 
the 3” end of the rmlC 
gene 
VT 
208478 Infant 81.95 0.17 4033  19F 19F 19F/15B/C Intact capsule synthesis 
genes- No genetic 
explanation 
VT 
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202731 Infant 81.26 0.08 Novel ST C 6712 28A/F  28A/F 6 nucleotide insertion in 
the wze gene 
NVT 
201297 Mother 81.95 0.34 5734  6A/B/C/D 6A/B/C/D 6A 12 nucleotide insertion in 
3’ end of the pseudogene 
HG262 
VT 
201794 Infant 78.82 0.8 Novel ST A 71 38 (low match 
35%) 
 Long branch, 
inconclusive 
Loss of cps locus --- 
201398 Mother 76.17 1.3 Novel ST H 3582 Classical NT  Long branch, 
inconclusive 
Capsule switch to 
classically NT locus 
--- 
201843 Infant 77.28 1.11 4040  Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
205597 Infant 75.37 0.96 Novel ST B 4040 Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
206158 Mother 78.28 0.89 Novel ST B 4040 Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
201133 Infant 64.27 3.02 344  Classical NT  Classical NT Classical NT --- 
202601 Mother 65.69 2.64 448  Classical NT  Classical NT Classical NT --- 
208136 Infant 66.12 2.67 448  Classical NT  Classical NT Classical NT --- 
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201017 Infant 17.54 43.18 Unknown  -   S.pseudopneumoniae --- 
209574 Infant 20.05 40.36 Unknown  -   S.pseudopneumoniae --- 
CSS3           
258M  89.95 1.43 10967  Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
141B  78.34 3.66 448  Classical NT  Classical NT Classical NT --- 
219B  76.67 4.01 344  Classical NT  Classical NT Classical NT --- 
034B  77.2 4.86 11729  Classical NT  Classical NT Classical NT --- 
153M  83.33 1.86 Novel ST 4040 Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
114B  87.33 1.67 4040  Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
223M  73.83 4.19 344  Classical NT  Classical NT Classical NT --- 
028B  77.13 4.1 344  Classical NT  Classical NT Classical NT --- 
284M  81.26 0.97 Unknown  14 14 14 Truncated wzg and wchA 
genes. 
VT 
092B  88.08 1.84 Novel ST 3582 Classical NT  Long branch, 
inconclusive 
Capsule switch to 
classically NT locus 
--- 
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113M  86.71 1.79 10967  Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
201B  78.23 4.84 11729  Classical NT  Classical NT Classical NT --- 
239B  93.26 0.12 989  12F 12F 12F No genetic explanation NVT 
248M  29.05 18.34 Unknown  alternative_ai
B_NT 
 Long branch, 
inconclusive 
Non-Pneumococcal 
streptococci 
--- 
236M  87.4 1.48 Unknown ~908 25F_or_25A 
(Low match 
29.1%) 
 14 --- --- 
073B  77.4 4.11 344  Classical NT  Classical NT Classical NT --- 
268M  76.62 4.11 344  Classical NT  Classical NT Classical NT --- 
268B  76.49 4.14 344  Classical NT  Classical NT Classical NT --- 
171B  76.89 3.59 448  Classical NT  Classical NT Classical NT --- 
003M  89.41 0.37 847  19A 19A 19A 4bp insertion on the wchA. 
3bp deletion in the rmlC 
gene 
VT 
314M  77.8 4.16 344  Classical NT  Classical NT Classical NT --- 
243M  75.91 3.63 448  Classical NT  Classical NT Classical NT --- 
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258B  93.29 0.1 989  12F 12F 12F No genetic explanation NVT 
S.pn S. pneumoniae S. pseudopn S. pseudopneumoniae   
a
CSS1 & 2 updated mechanisms for lack of capsular expression  
b 
Sample contaminated with unclassified organism, pneumococcal coverage sufficient for analysis and conclusion
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Figure legend 
Figure 1. Phylogenetic context of non-typable isolates. (i) Outer ring: Non-typable isolates from this 
study (green). (ii) Middle ring: This is the SeroBA serotype results of all the samples, the brown 
colour represents all isolates without a capsule locus. The leaves are labelled with either the isolate’s 
serotype (for context samples) or the isolate’s ID (study samples). (iii) The innermost ring depicts the 
major lineages, classical non-typables (purple), S. pseudopneumoniae (red) and typically 
encapsulated lineages (orange). 
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Tables  
Table 1 Characteristics of the study participants  
 CSS1*^ N=339 CSS2*^ N=350 CSS3^ N=351 P-value¬ 
Variable  n(%) n(%) n(%)  
Era** Before PCV13  1 year after 5 years after  
Health centre      
        Jammeh Foundation 229(67.6)  251(71.7) 250(71.2) 0.428 
        Sukuta  110(32.4) 99(28.3) 101(28.8)  
     
Gender a     
        Male 180(53.1) 165(47.3) 195(55.6) 0.069 
        Female  159(46.9) 184(52.7) 156(44.4)  
Infant’s age  (months)                
         Median (IQR) 8.2 (7.0,9.6) 7.6 (6.7,9.2) 8.0 (6.9,9.3)  
Infant PCV age (weeks)     
         Median (IQR)     
         Dose 1 10.3 (9.3,11.9) 10.6 (9.3, 12.3) 10.0 (9.0, 11.6)  
         Dose 2 15.9 (14.1, 18.3) 16.6 (14.6, 18.7) 15.4 (14.0-17.7)  
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         Dose 3b 21.9 (19.4, 24.9) 22.4 (20.1, 25.6) 20.7 (18.9, 23.4)  
Infant antibiotic use c      
         No 295(88.6) 319(92.2) 333(94.9) 0.010 
         Yes  38(11.4) 27(7.8) 18(5.1)  
     
Mother’s schooling d     
         None or < 1 year  134(41.7) 108(31.3) 135(39.5) <0.001 
         1-3 years  44(13.7) 35(10.1) 8(2.3)  
         4-6 years  78(24.3) 44(12.8) 26(7.6)  
         >6 years  65(20.3) 158(45.8) 173(50.6)  
Mother’s age (years)       
         Median(IQR) 24.5 (21.0,29.0) 25.0 (21.0,28.0) 25.0 (21.0, 30.0)  
Household size      
Median (IQR) 5.0 (4.0,7.0) 3.0 (3.0,5.0) Na  
*Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme 
of Immunization in The Gambia Roca et al, Vaccine 33 (2015) 7144–7151)  
^ There were 20 twins; CSS1 8, CSS2 3 & CSS3 9. The number of mothers was 331, 341 and 347 in CSS1, 2 and 3 
respectively.  
**PCV 7 intro in 2009, two years before the start of this study 
¬ p-value obtained from chi-square test. 
a
 one missing in CSS2  
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b
 one missing in CSS3 
b six missing CSS1 and 2 missing CSS2  
c
 antibiotic use within 4 months of survey  
d 
10 missing in CSS1 and 2 missing in CCS2 
Na   Not available as data were not collected 
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Table 2 
Prevalence of pneumococcal carriage in Infants before (CSS1) and one (CSS2) and five years (CSS3) after introduction of PCV13 into the Gambian EPI. 
 Prevalence of Carriage (%) CSS2 versus CSS3 CSS1 versus CSS3 
 
CSS1(N=339) CSS2(N=350) CSS3(N=351) RRadj p-value RRadj p-value 
Vaccine groups  
    
  
  PCV 13 VT 33.3 18.3 11.4 0.64(0.44,0.93) 0.021 0.60(0.50,0.71) <0.001 
PCV 13 NVT  53.1 66.9 74.4 1.12(1.01,1.23) 0.025 1.19(1.11,1.26) <0.001 
PCV13-7 VT 23.9 13.7 5.4 0.40(0.24,0.67) 0.001 0.23(0.14,0.37)  <0.001 
PCV 7 VT 9.4 4.9 6.0 1.30(0.67,2.53) 0.441 0.67(0.31,1.00) 0.051 
All serotypes 85.8 84.3 85.5 1.02(0.96,1.09) 0.459 1.00(0.97,1.04) 0.885 
     
  
  PCV 13 VT 
    
  
  1 0 0 0 NA  NA NA NA 
3 0 0.3 1.1 3.99(0.45,35.56) 0.215 NA NA 
4 0.6 0 0.9 NA  NA 1.20(0.49,2.94) 0.684 
5 0.3 1.4 0 NA  NA NA NA 
6A 15.3 5.7 0 NA  NA NA NA 
6B 0.9 0 0 NA  NA NA NA 
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7F 0 0 3.4 NA  NA NA NA 
9V 0 0 0.6 NA  NA NA NA 
14 0.6 0.9 0.6 0.66(0.11,3.96) 0.654 0.98(0.37,2.61) 0.972 
18C 0.6 0 0 NA  NA NA NA 
19A 8.3 6.3 0.9 0.14(0.04,0.45) 0.001 0.32(0.18,0.58) <0.001 
19F 5.6 1.7 2.8 1.66(0.61,4.53) 0.32 0.71(0.49,1.04) 0.078 
23F 1.5 2.3 1.1 0.50(0.15,1.64) 0.252 0.88(0.46,1.69) 0.699 
     
  
  PCV 13 NVT 
    
  
  10A 4.7 4 6 1.50(0.77,2.89) 0.232 1.13(0.82,1.55) 0.463 
13 3.5 3.4 3.4 1.00(0.45,2.19) 0.994 0.98(0.66,1.46) 0.931 
15B 8.3 9.1 6.8 0.75(0.45,1.24) 0.263 0.91(0.70,1.18) 0.48 
16 5.9 6.6 9.7 1.47(0.89,2.45) 0.135 1.28(0.98,1.67) 0.068 
19C 0.9 0.3 0 NA  NA NA NA 
21 3.2 4.9 7.1 1.47(0.81,2.67) 0.21 1.48(1.05,2.10) 0.026 
23B 1.5 3.1 4.6 1.45(0.68,3.08) 0.334 1.76(1.07,2.89) 0.026 
34 3.8 2.3 4.6 1.99(0.86,4.60) 0.106 1.09(0.76,1.56) 0.637 
35B 4.7 4.9 4.6 0.94(0.48,1.83) 0.852 0.98(0.70,1.38) 0.92 
NT 0.3 6.0 3.4 0.57(0.28,1.14) 0.112 3.40(1.23,9.42) 0.018 
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RR risk ratio, RRadj risk ratio adjusted for health centre, maternal age, and maternal education infant’s age, gender, and antibiotic intake within four weeks of the 
survey  
Table 3 
Prevalence of pneumococcal carriage in Mothers before (CSS1) and one (CSS2) and five years (CSS3) after introduction of PCV13 into the Gambian EPI.  
 Prevalence of Carriage (%) CSS2 versus CSS3 CSS1 versus CSS3 
 
CSS1(N=331) CSS2(N=347) CSS3(N=342) RRadj pvalue RRadj p-value 
Vaccine group 
    
  
  PCV 13 VT 6.6 8.4 5.6 0.58(0.33,1.02) 0.06 0.92(0.67,1.27) 0.627 
PCV 13 NVT 16.6 16.1 32.2 2.01(1.51,2.67) <0.001 1.40(1.20,1.63) <0.001 
PCV 13-7 VT 3.9 6.1 2.3 0.34(0.15,0.74) 0.007 0.65(0.28,,1.52) 0.319 
PCV 7 VT  2.7 2.6 3.2 1.14(0.46,2.79) 0.782 0.99(0.40-2.48) 0.989 
All serotypes 23.0 24.2 37.7 1.51(1.20,1.91) <0.001 1.29(1.14,1.47) <0.001 
     
  
  PCV13 VT 
    
  
  1 0.3 0 0 NA  NA NA NA 
3 0 0.3 1.8 6.09(0.74,50.38) 0.094 NA NA 
4 0.6 0.6 0.6 1.01(0.14,7.17) 0.988 0.98(0.37,2.62) 0.974 
5 0 0.9 0 NA  NA NA NA 
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6A 1.8 2 0 NA  NA NA NA 
6B 0 0 0 NA  NA NA NA 
7F 0 0 0.3 NA  NA NA NA 
9V 0 0 0.3 NA  NA NA Na 
14 0.6 0.3 0.6 2.03(0.18,22.31) 0.563 0.98(0.37,2.62) 0.974 
18C 0.3 0.6 0.3 0.51(0.05,5.58) 0.579 0.98(0.25,3.93) 0.982 
19A 1.8 3.2 0.3 0.09(0.01,0.71) 0.022 0.40(0.14,1.16) 0.091 
19F 0.6 0.3 1.2 4.06(0.46,36.19) 0.21 1.39(0.60,3.24) 0.444 
23F 0.6 0.9 0.3 0.34(0.04,3.24) 0.347 0.70(0.21,2.31) 0.553 
     
  
  PCV13 NVT 
    
  
  10A 0.6 0.3 2.3 8.12(1.02,64.65) 0.048 1.97(0.91,4.26) 0.086 
13 0.6 1.7 0.6 0.34(0.07,1.67) 0.183 0.98(0.37,2.62) 0.974 
15B 0.6 1.7 1.2 0.68(0.19,2.38) 0.542 1.39(0.60,3.24) 0.444 
16 2.4 0.6 2.3 4.06(0.87,19.00) 0.075 0.98(0.61,1.60) 0.947 
19C 1.2 0 0 NA   NA NA 
21 0.9 0.9 2.9 3.38(0.94,12.19) 0.063 1.80(0.95,3.41) 0.073 
23B 0 0.9 2.0 2.37(0.62,9.09) 0.209 NA NA 
34 1.2 1.2 1.8 1.52(0.43,5.35) 0.513 1.20(0.64,2.26) 0.561 
35B 1.8 0.6 1.8 3.04(0.62,14.99) 0.171 0.98(0.56,1.72) 0.954 
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NT 0.3 1.4 3.2 2.23(0.78,6.36) 0.133 3.26(1.17,9.06) 0.023 
RR risk ratio, RRadj risk ratio adjusted for health centre, maternal age, and maternal education 
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Table 4 Results of whole genome sequencing of non-typeable isolatesa 
Isolate N Mother 
/Infant 
S.pn  % 
reads 
S.pseudopn % 
reads 
ST Nearest 
ST 
Capsular locus 
top hit 
Serotype 
specific 
sequence 
detected 
Ancestral 
capsular type 
from phylogeny 
Conclusion VT 
/NVT 
CSS1           
108887 Infant 78.08 0.71 3407  16F 16F 16F Wzd gene loss and 
truncated wzh 
NVT 
105098 Mother 80.51 0.14 1778  34 34 34 Intact capsule synthesis 
genes- No genetic 
explanation 
NVT 
104550 Mother 19.47 40.9 Unknown  -   S.pseudopneumoniae --- 
CSS2           
201376 Infant 80.46 0.25 5521  10A 10A 10A Intact capsule synthesis 
genes- No genetic 
explanation 
NVT 
207381 Infant 82.09 0.4 Novel ST D 2052 20 20 Long branch, Truncated whaF and wzx NVT 
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inconclusive genes 
206628 Infant 81.38 0.08 989  12F 12F/A/46 12F/A/46 Intact capsule synthesis 
genes- No genetic 
explanation 
NVT 
210240 Infant 80.96 0.08 989  12F 12F/A/46 12F/A/46 Intact capsule synthesis 
genes- No genetic 
explanation 
NVT 
210201 Infant 83.51 0.08 2447  14 14 14 Truncated glycosyl 
transferase genes, wciY 
and lrp 
VT 
201867
b
 Infant 46.64 0.57 Novel ST B 4040 Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
200954 Mother 81.22 0.25 Novel ST G 975 15B/C 15B/C 15B/C 12 nucleotide insertion at 
the 5’ end of the initial 
transferase gene, wchA 
NVT 
206379 Infant 81.51 0.16 4033  15B/C 15B/C 15B/C 12 nucleotide insertion at 
the 5’ end of the initial 
transferase gene, wchA 
NVT 
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207139 Infant 76.55 0.57 3407  16F 16F 16F Wzd gene loss and 
truncated wzh 
NVT 
210300 Infant 78.96 0.62 Novel ST F 3407 16F 16F 16F Wzd gene loss and 
truncated wzh 
NVT 
210092 Infant 80.13 0.28 Novel ST E 847 19A 19A 19A 3 nucleotide deletion at the 
3” end of the rmlC gene 
VT 
210344 Infant 79.93 0.19 Unknown 7661 19B  19B Intact capsule synthesis 
genes- No genetic 
explanation 
NVT 
206438 Infant 81.8 0.1 202  19A 19A Long branch, 
inconclusive 
3 nucleotide deletion at 
the 3” end of the rmlC 
gene 
VT 
208478 Infant 81.95 0.17 4033  19F 19F 19F/15B/C Intact capsule synthesis 
genes- No genetic 
explanation 
VT 
202731 Infant 81.26 0.08 Novel ST C 6712 28A/F  28A/F 6 nucleotide insertion in 
the wze gene 
NVT 
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201297 Mother 81.95 0.34 5734  6A/B/C/D 6A/B/C/D 6A 12 nucleotide insertion in 
3’ end of the pseudogene 
HG262 
VT 
201794 Infant 78.82 0.8 Novel ST A 71 38 (low match 
35%) 
 Long branch, 
inconclusive 
Loss of cps locus --- 
201398 Mother 76.17 1.3 Novel ST H 3582 Classical NT  Long branch, 
inconclusive 
Capsule switch to 
classically NT locus 
--- 
201843 Infant 77.28 1.11 4040  Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
205597 Infant 75.37 0.96 Novel ST B 4040 Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
206158 Mother 78.28 0.89 Novel ST B 4040 Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
201133 Infant 64.27 3.02 344  Classical NT  Classical NT Classical NT --- 
202601 Mother 65.69 2.64 448  Classical NT  Classical NT Classical NT --- 
208136 Infant 66.12 2.67 448  Classical NT  Classical NT Classical NT --- 
201017 Infant 17.54 43.18 Unknown  -   S.pseudopneumoniae --- 
209574 Infant 20.05 40.36 Unknown  -   S.pseudopneumoniae --- 
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CSS3           
258M  89.95 1.43 10967  Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
141B  78.34 3.66 448  Classical NT  Classical NT Classical NT --- 
219B  76.67 4.01 344  Classical NT  Classical NT Classical NT --- 
034B  77.2 4.86 11729  Classical NT  Classical NT Classical NT --- 
153M  83.33 1.86 Novel ST 4040 Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
114B  87.33 1.67 4040  Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
223M  73.83 4.19 344  Classical NT  Classical NT Classical NT --- 
028B  77.13 4.1 344  Classical NT  Classical NT Classical NT --- 
284M  81.26 0.97 Unknown  14 14 14 Truncated wzg and wchA 
genes. 
VT 
092B  88.08 1.84 Novel ST 3582 Classical NT  Long branch, 
inconclusive 
Capsule switch to 
classically NT locus 
--- 
113M  86.71 1.79 10967  Classical NT  14 Capsule switch from 14 to 
classically NT locus 
VT 
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201B  78.23 4.84 11729  Classical NT  Classical NT Classical NT --- 
239B  93.26 0.12 989  12F 12F 12F No genetic explanation NVT 
248M  29.05 18.34 Unknown  alternative_ai
B_NT 
 Long branch, 
inconclusive 
Non-Pneumococcal 
streptococci 
--- 
236M  87.4 1.48 Unknown ~908 25F_or_25A 
(Low match 
29.1%) 
 14 --- --- 
073B  77.4 4.11 344  Classical NT  Classical NT Classical NT --- 
268M  76.62 4.11 344  Classical NT  Classical NT Classical NT --- 
268B  76.49 4.14 344  Classical NT  Classical NT Classical NT --- 
171B  76.89 3.59 448  Classical NT  Classical NT Classical NT --- 
003M  89.41 0.37 847  19A 19A 19A 4bp insertion on the wchA. 
3bp deletion in the rmlC 
gene 
VT 
314M  77.8 4.16 344  Classical NT  Classical NT Classical NT --- 
243M  75.91 3.63 448  Classical NT  Classical NT Classical NT --- 
258B  93.29 0.1 989  12F 12F 12F No genetic explanation NVT 
S.pn S. pneumoniae S. pseudopn S. pseudopneumoniae   
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a
CSS1 & 2 updated mechanisms for lack of capsular expression  
b 
Sample contaminated with unclassified organism, pneumococcal coverage sufficient for analysis and conclusion
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